Share this article

'Mistake' Corrected: Overstock Invests in Blockchain Startup Symbiont

Overstock's investment arm has backed Symbiont following the successful passage of the Delaware blockchain amendments.

Updated Sep 11, 2021, 1:33 p.m. Published Jul 19, 2017, 7:59 p.m.
keyboard, money button

The blockchain branch of retail giant Overstock today announced its first investment in Symbiont, a startup aimed at streamlining the way financial instruments are traded.

The investment by Overstock's Medici Ventures in Symbiont, for undisclosed terms, is being positioned by both firms as the beginning of a collaborative effort to bring to life a new era of securities traded directly on a blockchain.

STORY CONTINUES BELOW
Don't miss another story.Subscribe to the Crypto Daybook Americas Newsletter today. See all newsletters

But the investment almost didn't happen. Earlier this year, Medici president Jonathan Johnson had considered joining an earlier round, only to pass on the opportunity — it turns out, temporarily.

Medici Ventures president Jonathan Johnson explained how Symbiont fits into the company’s portfolio, and why they decided to pass on the company the first time around.

He told CoinDesk:

"We made a mistake."

Founded in 2015, Symbiont has raised a total of about $7 million to build out private blockchain solutions, including most recently an undisclosed amount from Hundsun, a tech firm backed by Alibaba founder Jack Ma.

Earlier this month, Symbiont was among several organizations involved in helping push for blockchain regulation in the State of Delaware, which celebrated the successful passage of the amendments.

Both Symboint and fellow Medici Ventures portfolio company T0 stand to benefit from the amendments that explicitly recognized a corporation’s right to use a blockchain to track stock shares.

Even as Johnson acknowledged that the companies' work with stocks was "somewhat competitive," he distinguished Symbiont’s Orebits work with selling gold on a blockchain and other initiatives as potentially being of use to each other.

"There's some overlap," said Johnson. "But we see them as mostly complimentary."

Blockchain strategy

In contrast to Medici Ventures investments in Bitt and T0, which Johnson described as involving a "significant role," he said his firm’s work with Symbiont is of a more strategic nature.

Symbiont president Caitlin Long elaborated on what that means when she told CoinDesk the investment conversation was "resurrected" in the build-up to the passage of the Delaware amendments.

In conversation, Long said that while Symbiont wants to be the first private company to move all its shares to a blockchain, Medici parent Overstock wants to be the first public company to do so.

She concluded:

"They put a proposal on the table about three weeks ago, and moved very quickly once we both realized we wanted to do this."

Money image via Shutterstock

More For You

Protocol Research: GoPlus Security

GP Basic Image

What to know:

  • As of October 2025, GoPlus has generated $4.7M in total revenue across its product lines. The GoPlus App is the primary revenue driver, contributing $2.5M (approx. 53%), followed by the SafeToken Protocol at $1.7M.
  • GoPlus Intelligence's Token Security API averaged 717 million monthly calls year-to-date in 2025 , with a peak of nearly 1 billion calls in February 2025. Total blockchain-level requests, including transaction simulations, averaged an additional 350 million per month.
  • Since its January 2025 launch , the $GPS token has registered over $5B in total spot volume and $10B in derivatives volume in 2025. Monthly spot volume peaked in March 2025 at over $1.1B , while derivatives volume peaked the same month at over $4B.

More For You

Bitcoin’s Deep Correction Sets Stage for December Rebound, Says K33 Research

(Unsplash)

K33 Research says market fear is outweighing fundamentals as bitcoin nears key levels. December could offer an entry point for bold investors.

What to know:

  • K33 Research says bitcoin’s steep correction shows signs of bottoming, with December potentially marking a turning point.
  • The firm has argued that the market is overreacting to long-term risks while ignoring near-term signals of strength, like low leverage and solid support levels.
  • With likely policy shifts ahead and cautious positioning in futures, K33 sees more upside potential than risk of another major collapse.